Searches for FXR ligands on the database clinicaltrials.gov show numerous studies aiming to apply FXR ligands for many types of diseases including cholestasis but also alcohol-, obesity-, metabolic syndrome-, and diabetes-related liver injuries (e.g., alcoholic hepatitis, NASH, and NAFLD). The gene discussed is NR1H4; the disease is obesity due to melanocortin 4 receptor deficiency.